Azo compounds in colon-specific drug delivery

Expert Opinion on Drug Delivery

Volumn 4, Issue 5, 2007, Pages 547-560

  Roldo, Marta ^a   Barbu, Eugen ^a   Brown, James F ^a   Laight, David W ^a   Smart, John D ^b   Tsibouklis, John ^a  

^a UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^b UNIVERSITY OF BRIGHTON   (United Kingdom)

Author keywords

Azo polymers; Azo reduction; Biodegradation; Colonic targeting; Drug delivery

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; 9 AMINOCAMPTOTHECIN; APAZA; AZO COMPOUND; BALSALAZINE; CYCLOSPORIN A; DRUG CARRIER; EUDRAGIT; FLUOROURACIL; HEXAMETHYLENE DIISOCYANATE; IBUPROFEN; INSULIN; IPSALAZINE; MACROGOL; MESALAZINE; OLSALAZINE; POLY(METHYL METHACRYLATE); POLYACRYLIC ACID; POLYSTYRENE; POLYURETHAN; PRODRUG; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; VASOPRESSIN;

CHEMICAL STRUCTURE; COLITIS; COLON; COLON CANCER; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG RELEASE; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; ENZYME MECHANISM; HYDROGEL; HYDROPHILICITY; MACROMOLECULE; NONHUMAN; PH MEASUREMENT; PRESSURE MEASUREMENT; REVIEW; STIMULUS RESPONSE; TIMED DRUG RELEASE; TISSUE SPECIFICITY; ULCERATIVE COLITIS;

ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; AZO COMPOUNDS; COLON; COLONIC DISEASES; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROGELS; PHARMACEUTICAL PREPARATIONS; POLYMERS; PRODRUGS;

EID: 35148830086     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.5.547     Document Type: Review

References (113)

1. RUBINSTEIN A: Colonic drug delivery. Drug Discov. Today (2005) 2(1):33-37.
2. FRIEND DR: New oral delivery systems for the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:247-265.
3. KLOTZ U, SCHAWAB M: Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:267-279.
4. CHOURASIA MK, JAIN SK: Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharmaceut. Sci. (2003) 6:33-66.
5. SINHA VR, KUMRIA R: Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. (2003) 18:3-18.
6. VANDAMME TF, LENOURRY A, CHARRUEAU C, CHAUMEIL JC: The use of polysaccharides to target the colon. Carbohydrate Polym. (2002) 48:219-231.
7. SINHA VR, KUMRIA R: Polysaccharides in colon-specific drug delivery. Int. J. Pharm. (2001) 224:19-38.
8. SINHA VR, KUMRIA R: Colonic drug delivery: prodrug approach. Pharm. Res. (2001) 18:557-564.
9. LEOPOLD CS: Coated dosage forms for colon-specific drug delivery. PSTT (1999) 2:197-204.
10. KINGET R, KALALA W, VERVOOT L, VAN DEN MOOTER G: Colonic drug targeting. J. Drug Target. (1998) 6:129-149.
11. WATTS PJ, ILLUM L: Colonic drug delivery. Drug Dev. Ind. Pharm. (1997) 23(9):893-913.
12. VAN DEN MOOTER G, MARIS B, SAMYN C, AUGUSTIJNS P, KINGET R: Use of azo polymers for colon-specific drug delivery. J. Pharm. Sci. (1997) 86: 1321-1327.
13. FRIEND DR: Colon-specific drug delivery. Adv. Drug Deliv. Rev. (1991) 7:149-199.
14. VAN DEN MOOTER C: Colon drug delivery. Expert Opin. Drug. Deliv. (2006) 3(1):111-125.
15. IKESUE K, KOPEČKOVA P, KOPEČEK J: Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. (1993) 95:171-179.
16. LANGGUTH P, BREVES G, STOCKLI A, MERKLE HP, WOLFFRAM S: Colonic absorption and bioavailability of the pentapeptide metkephamid in the rat. Pharm. Res. (1994) 11:1640-1645.
17. FARA JW, MYRBACK RE: Formulation and dosage form design in drug-induced topical irritation of the gastrointestinal tract. Pharm. Res. (1990) 7:616-621.
18. RUBINSTEIN A: Approaches and opportunities in colon-specific drug delivery. Crit. Rev. Ther. Drug Carrier Syst. (1995) 12(2&3):101-149.
19. WILSON CG, WASHINGTON N: Physiological Pharmaceutics: Biological Barriers to Drug Absorption. (Ed.), Wiley John and sons, Chichester, UK (1989).
20. DAVIS SS, HARDY JD, TAYLOR MJ, WHALLEY DR, WILSON CG: A comparative study of the gastrointestinal tansit of a pellet and tablet formulation. Int. J. Pharm. (1984) 21:116-117.
21. DAVIS SS, NORRING-CHRISTENSEN F, KHOSLA R, FEELY LC: Gastric emptying of large single unit dosage forms. J. Pharm. Pharmacol. (1988) 40:205-207.
22. DEVEREUX JE, NEWTON JM, SHORT MB: The influence of density on the gastrointestinal transit of pellets. J. Pharm. Pharmacol. (1990) 42:500-501.
23. PRICE JMC, DAVIS SS, WILDING IR: The effect of fibre on gastrointestinal transit times in vegetarians and omnivores. Int. J. Pharm. (1991) 76:123-141.
24. MADSEN JL: Effect of gender, age and body mass index on gastrointestinal transit times. Dig. Dis. Sci. (1992) 37:1548-1553.
25. WILDING IR, COUPE AJ, DAVIS SS: The role of α scintigraphy in oral drug delivery. Adv. Drug Deliv. Rev. (1991) 7:87-117.
26. DAVIS SS, HARDY JG, FARA JW: Alimentary tract and pancreas: transit of pharmaceutial dosage forms through the small intestine. Gut (1986) 27:886-892.
27. DAVIS SS: The design and evaluation of controlled release systems for the gastrointestinal tract. J. Control. Rel. (1985) 2:27-38.
28. PHILIPS SF: Transit across the ileocolonic junction. In: Drug Delivery in the Gastrointestinal Tract. Hardy JD et al. (Eds), Ellis Horwood Ltd., Chichester, UK (1989):63-76.
29. EVANS DF, PYE G, BRAMLEY R, CLARK AG, DYSON TJ: Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut (1988) 29: 1035-1041.
30. RAIMUNDO AH, EVANS DF, ROGERS J, SILK DBA: Gastrointestinal pH profiles in ulcerative colitis. Gastroenterology (1992) 104:A681.
31. HASTEWELL J, WILLIAMSON I, MACKAY M: Cell biology and active transport processes in the colon. Adv. Drug Deliv. Rev. (1991) 7:119-147.
32. SICCARDI D, TURNER JR, MRSNY RJ: Regulation of intestinal epithelial function: a link between opportunities for macromolecular drug delivery and inflammatory bowel disease. Adv. Drug Deliv. Rev. (2005) 57:219-235.
33. MRSNY R: The colon as a site for drug delivery. J. Control Rel. (1992) 22:15-34.
34. VAN HOOGDALEM EJ, DE BOER AG, BRIEMER D: Intestinal drug absorption enhancement: an overview. Phamacol. Ther. (1989) 44:407-443.
35. TOZAKI H, KOMOIKE J, TADA C et al.: Chitosan capsules for colon-specific drug delivery: improvement of insulin absorption from the rat colon. J. Pharm. Sci. (1990) 86(9):1016-1021.
36. LEE VHL, YAMAMOTO A: Penetration and enzymatic barriers to peptide and protein absorption. Adv. Drug Deliv. Rev. (1989) 4(2):171-207.
37. YAMAMOTO A, HAYAKAWA E, LEE VH: Insulin and proinsulin proteolysis in mucosal homogenates of the albino rabbit: implications in peptide delivery from nonoral routes. Life Sci. (1990) 47(26):2465-2474.
38. BAI JPF: Colonic delivery of peptide and protein drugs: consideration of intracellular proteolytic enzymes. STP Pharma Sci. (1995) 5(1):30-35.
39. PEETERS M, GEYPENS B, CLAUS D et al.: Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 113:802-807.
40. TAYLOR CT, DZUS AL, COLGAN SP: Autocrine regulation of epithelial permeability by hypoxia: role of polarized release of TNF-α. Gastroenterology (1998) 114:657-668.
41. SAVAGE G: Microbial ecology of the gastrointestinal tract. Annu. Rev. Microbiol. (1997) 31:107-133.
42. HILL MJ, DRASAR BS: The normal colonic bacterial flora. Gut (1975) 16:318-323.
43. GOLDMAN P: Biochemical pharmacology of the intestinal flora. Annu. Rev. Pharmacol. Toxicol. (1978) 18:523-539.
44. KEIGHLEY MRB, ARABI Y, DIMOCK F et al.: Influence of inflammatory bowel disease on intestinal microflora. Gut (1978) 19:1099-1106.
45. RUBINSTEIN A: Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. (1990) 11:465-475.
46. SCHELINE RR: Metabolism of foreign compounds by gastrointestinal microorganism. Pharmacol Rev. (1973) 25:451-523.
47. WILDING IR, DAVIS SS, O'HAGAN OT: Targeting drugs and vaccines to the gut. Phamacol Ther. (1994) 62:97-124.
48. LARSEN GL, LARSON JP, GUSTAFSSON JA: Cysteine conjugate β-lyase in the gastrointestinal bacterium Fusobacterium necrophorum. Xenobiotica (1983) 13:687-693.
49. MURAOKA M, HU Z, SHIMOKAWA T et al.: Evaluation of intestinal pressure-controlled colon delivery capsule containing caffeine as a model drug in human volunteers. J. Control. Rel. (1998) 52:119-129.
50. RADOMSKI JL, MELLINGER TJ: Fate and excretion in rats of soluble azo dyes. J. Pharmacol. Exp. Ther. (1962) 136:259-266.
51. GINGELL R, WALKER R: Mechanism of azo reduction by Streptococcus faecalis. II. The role of soluble flavins. Xenobiotica (1971) 1:231-239.
52. GRIM Y, KOPEČEK J: Bioadhesive water-soluble polymeric drug carriers for site-specific oral drug delivery. Synthesis, characterization, and release of 5-aminosalicylic acid by Streptococcus faecium in vitro. N. Polym. Mater. (1991) 3(1):49-59.
53. BRAGGER JL, LLOYD AW, SOOZANDEHFAR SH et al.: Investigations into the azo reducing activity of a common colonic microorganism. Int. J. Pharm. (1997) 157:61-71.
54. MUTAFOV S, AVRAMOVA T, STEFANOVA L, ANGELOVA B: Decolorization of acid orange 7 by bacteria of different tinctorial type: a comparative study. World J. Microbiol. Biotechnol. (2007) 23(3):417-422.
55. STOLZ A: Basic and applied aspects in the microbial degradation of azo dyes. Appl. Microbiol. Biotechnol. (2001) 56:69-80.
56. ITO K, NAKANISHI M, LEE WC et al.: Three-dimensional structure of Azo R from Escherichia coli - an oxidereductase conserved in microorganisms. J. Biol. Chem. (2006) 281(29):20567-20576.
57. DOS SANTOS A, CERVANTES F, VAN LIER J: Review paper on current technologies for decolourisation of textile wastewaters: perspectives for anaerobic biotechnology. Bioresou. Technol. (207) 98:2369-2385.
58. BRØNDSTED H, KOPEČEK J: Hydrogels for site-specific dug delivery to the colon: in vitro and in vivo degradation. Pharm. Res. (1992) 9:1540-1545.
59. KIMURA Y, MAKITA Y, KUMAGAI T et al.: Degradation of azo-containing polyurethane by the action of intestinal flora: its mechanism and applications as drug delivery system. Polymer (1992) 33:5294-5299.
60. YAMAOKA T, MAKITA Y, SASATANI H, KIM SI, KIMURA Y: Linear type azo-containing polyurethane as drug-coating material for colon-specific delivery: its properties, degradation behavior, and utilization for drug formulation. J. Control. Rel. (2000) 66:187-197.
61. LLOYD AW, MARTIN GP, SOOZANDEHFAR SH: Azopolymers: a means of colon specific drug delivery? Int. J. Pharm. (1994) 106:255-260.
62. NAM S, RENGANATHAN V: Non-enzymatic reduction of azo dyes by NADH. Chemosphere (2000) 40:351-357.
63. BROWN MA, DEVITO SC: Predicting azo-dye toxicity. Crit. Rev. Environ. Sci. Technol. (1993) 23(3):249-324.
64. KAHN AKA, PIRIS J, TRUELOVE SC: An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet (1977) 2:225-232.
65. KAHN AKA, TRUELOVE SC, ARONSEQ JK: The disposition and metabolism of sulphasalazine (salicylazosulphapiridine). Br. J. Clin. Pharmacol. (1982) 13:523-528.
66. VAN HOZEGARD RA: Pharmacokinetics of olsalazine and its metabolites. Scand. J. Gastroenterol. (1988) 23S(148):17-20.
67. WILLOUGHBY CP, COWAN RE, GOULD SR, MACHELL RJ, STEWART JB: Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand. J. Gastroenterol. (1988) 23(Suppl. 148):40-44.
68. BROWN JP, MCGARRAUGH GV, PARKINSON TM, WINGARD RE, ONDERDONK AB: A polymeric drug for the treatment of inflammatory bowel disease. J. Med. Chem. (1983) 26:1300-1307.
69. MCVEY DC, LIDDLE RA, RIGGS-SAUTHIER J, EKWURIBE N, VIGNA SR: Inhibition of Clostridium difficile toxin A-induced colitis in rats by APAZA. Dig. Dis. Sci. (2005) 50(3):565-573.
70. WIWATTANAPATAPEE R, LOMLIM L, SARAMUNEE K: Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J. Control. Rel. (2003) 88:1-9.
71. SCHACHT E, GEVAERT A, REFAIE KENAWY E et al.: Polymers for colon specific drug delivery. J. Control. Rel. (1996) 39:327-338.
72. MOLLY K, VANDE WOESTYNE M, VERSTRAETE W: Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem. Appl. Microbiol. Biotechnol. (1993) 39:254-258.
73. MAHKAM M, ASSADI MG, ZAHEDIFAR R, RAMESH M, DAVARAN S: Linear type azo-containing polyurethanes for colon-specific drug delivery. J. Bioact. Compat. Polym. (2004) 19:45-53.
74. LAI J, WANG LQ KT, ZHAO C, SUN W: Linear azo polymer containing conjugated 5,5′-azodisalicylic acid segments in the main chain: synthesis, characterization, and degration. Macromol. Rapid Commun. (2005) 26:1572-1577.
75. MAHKAM M, ASSADI MG, ZAHEDIFAR R et al.: Synthesis and evaluation of a new linear azo-polymer for colonic targeting. Des. Monomers Polym. (2004) 7(4):351-359.
76. DAVARAN S, RASHIDI MR, HANAEE J, KHANI A, HASHEMI M: Synthesis and degradation characteristics of polyurethanes containing azo derivatives of 5-amino salicylic acid. J. Bioact. Compat. Polym. (2006) 21:315-326.
77. KLOTZ U: Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig. Liver Dis. (2005) 37(6):381-388.
78. KOPEČKOVA P, KOPEČEK J: Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl)methacrylamide copolymers by azoreductases in vitro. Makromol. Chem. (1990) 191:2037-2045.
79. SAKUMA S, LU ZR, KOPEČKOVA P, KOPEČEK J: Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocaptothecin. J. Control. Rel. (2001) 75:365-379.
80. LU ZR, GAO SQ KOPEČKOVA P, KOPEČEK J: Synthesis of bioadhesive lectin-HPMA copolymer-cyclosporin conjugates. Bioconjug. Chem. (2000) 11:3-7.
81. IZHAR M, NUCHAMOWITZ Y, MIRELMAN D: Adherence of Shigella flexneri to guinea pig intestinal cells is mediated by a mucosal adhesion. Infect. Immun. (1982) 35:1110-1118.
82. MIRELMAN D, IZHAR M, ESHDAT-TOKAI J: Carbohydrate recognition mechanisms which mediate microbial adherence to mammalian mucosal surfaces. J. Exp. Clin. Med. (1982) 7(Suppl.):177-183.
83. SAKUMA S, LU ZR, PECHAROVA B, KOPEČKOVA P, KOPEČEK J: N-(2-hydroxypropyl)methacrylamide copolymer-9-aminocamptothecin conjugate: colon-specific delivery in rats. J. Bioact. Compat. Polym. (2002) 17:305-319.
84. TOKI BE, CERVENY CG, WAHL AF, SENTER PD: Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org Chem. (2002) 67(2002):1866-1872.
85. DE GROOT FM, LOOS WJ, KOEKKOEK R et al..: Elongated multiple electronic cascade and cyclization spacer system in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. (2001) 66:8815-8830.
86. GAO SQ, LU ZR, PETRI B, KOPEČKOVA P, KOPEČEK J: Colon-specific 9-aminocamptothecin-HPMA copolymer conjugates containing a 1,6-elimination spacer. J. Control. Rel. (2006) 110:323-331.
87. GAO SQ, LU ZR, KOPEČKOVA P, KOPEČEK J: Biodistribution and pharmacokinetics of colon-specific HPMA copolymer-9-aminocamptothecin conjugate in mice. J. Control. Rel. (2007) 117:179-185.
88. KAKOULIDES E, SMART JD, TSIBOUKLIS J: Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: synthesis and characterisation. J. Control. Rel. (1998) 52(3):291-300.
89. KAKOULIDES EP, SMART JD, TSIBOUKLIS J: Azocrosslinked poly(acrylic acid) for colonic delivery and adhesion specificity: in vitro degradation and preliminary ex vivo bioadhesion studies. J. Control. Rel. (1998) 54(1):95-109.
90. ROLDO M, BARBU E, BROWN J et al.: Orally administered, colon-specific mucoadhesive azopolymer particles for the treatment of inflammatory bowel disease: an in vivo study. J. Biomed. Mater. Res. A (2006) 79A(3):706-715.
91. APPLEYARD CB, WALLACE JL: Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am. J. Physiol. Gastrointest. Liver Physiol. (1995) 269:G119-G125.
92. SAKKINEN M, MARVOLA J, KANERVA H et al.: Are chitosan formulations mucoadhesive in the human small intestine? An evaluation based on γ scintigraphy. Int. J. Pharm. (2006) 307:285-291.
93. PATEL M, SMART J, NEVELL T et al.: Mucin/poly(carboxylic acid) interactions: a spectroscopic investigation of mucoadhesion. Biomacromolecules (2003) 4(5):1184-1190.
94. HOFFMAN AS: Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. (2002) 54:3-12.
95. GUPTA P, VERMANI K, GARG S: Hydrogels: from controlled release to pH-responsive drug delivery. Drug Discov. Today (2002) 7(10):569-579.
96. HAMIDREZA G, KOPEČKOVA P, YEH PY, KOPEČEK J: Biodegradable and pH-sensitive hydrogels: synthesis by a polymer-polymer reaction. Macromol. Chem. Phys. (1996) 197:965-980.
97. BRØNDSTED H, KOPEČEK J: Hydrogels for site-specific oral drug delivery: synthesis and characterization. Biomaterials (1991) 12:584-592.
98. YEH PY, BERENSON MM, SAMOWITZ WS, KOPEČKOVA P, KOPEČEK J: Site-specific drug delivery and penetration enhancement in the gastrointestinal tract. J. Control. Rel. (1995) 36:109-124.
99. GHANDEHARI H, KOPEČKOVA P, KOPEČEK J: In vitro degradation of pH-sensitive hydrogels containing aromatic azo bonds. Biomaterials (1997) 18:861-872.
100. SHANTHA KL, RAVICHANDRAN P, PANDURAGA RAO K: Azo polymeric hydrogels for colon targeted drug delivery. Biomaterials (1995) 16:1313-1318.
101. STUBBE B, MARIS B, VAN DEN MOOTER G, DE SMEDT SC: The in vitro evaluation of "azo containing polysaccharide gels" for colon delivery. J. Control. Rel. (2001) 75:103-114.
102. VERVOOT L, VAN DEN MOOTER G, AUGUSTIJNS P et al.: Inulin hydrogels as carriers for colonic drug targeting. I. Synthesis and characterisation of methacrylated inulin and hydrogel formation. Pharm. Res. (1997) 12: 1730-1737.
103. MARIS B, VERHEYDEN L, VAN REETH K et al.: Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. Int. J. Pharm. (2001) 213: 143-152.
104. LIU ZL, HU H, ZHUO RX: Konjac glucomannan-graft-acrylic acid hydrogels containing azo crosslinker for colon-specific delivery. J. Polym. Sci. [A1] (2004) 42(17):4370-4378.
105. YIN Y, YANG YJ, XU H: Hydrophobically modified hydrogels containing azoaromatic coss-links: swelling properties, degradation in vivo and application in drug delivery. Eur. Polym. J. (2002) 38:2305-2311.
106. SAFFRAN M, KUMAR GS, SAVARUAR C et al.: A new approach to the oral administration of insulin and other peptide drug. Science (1986) 233:1081-1084.
107. TOZAKI H, NISHIOKA J, KOMOIKE J et al.: Enhanced absorption of insulin and (Asu1,7)Eel-calcitonin using novel azopolymer-coated pellets for colon-specific drug delivery. J. Pharm. Sci. (2001) 90:89-97.
108. VAN DEN MOOTER G, SAMYN C, KINGET R: Azo polymers for colon-specific drug delivery. Int. J. Pharm. (1992) 87:37-46.
109. VAN DEN MOOTER G, SAMYN C, KINGET R: Characterization of colon-specific azo polymers: a study of the swelling properties and the permeability of isolated polymer films. Int. J. Pharm. (1994) 111:127-136.
110. VAN DEN MOOTER G, SAMYN C, KINGET R: The relation between swelling properties and enzymatic degradation of azo polymers designed for colon-specific drug delivery. Pharm. Res. (1994) 11: 1737-1741.
111. JAIN SK, CHOURASIA MK, DENGRE R: Azo polymers for colon targeted drug delivery. Indian J. Pharm. Sci. (2005) 67(1):43-50.
112. LOW PS: Folate receptor-targeted imaging and therapeutic agents for cancer and inflammation. (Ed.), Proceedings of International Symposium on Polymer Therapeutics, Berlin (DE) (2007).
113. PAULOS CM, TURK MJ, BREUR GJ, LOW PS: Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv. Drug Deliv. Rev. (2004) 56(8):1205-1217.